Literature DB >> 20514509

Italian consensus statement on paediatric HIV infection.

C Giaquinto1, M Penazzato, R Rosso, S Bernardi, O Rampon, P Nasta, A Ammassari, A Antinori, R Badolato, G Castelli Gattinara, A d'Arminio Monforte, M De Martino, A De Rossi, P Di Gregorio, S Esposito, F Fatuzzo, S Fiore, A Franco, C Gabiano, L Galli, O Genovese, V Giacomet, A Giannattasio, C Gotta, A Guarino, A Martino, F Mazzotta, N Principi, M B Regazzi, P Rossi, R Russo, M Saitta, F Salvini, S Trotta, A Viganò, G Zuccotti, G Carosi.   

Abstract

The objective of this document is to identify and reinforce current recommendations concerning the management of HIV infection in infants and children in the context of good resource availability. All recommendations were graded according to the strength and quality of the evidence and were voted on by the 57 participants attending the first Italian Consensus on Paediatric HIV, held in Siracusa in 2008. Paediatricians and HIV/AIDS care specialists were requested to agree on different statements summarizing key issues in the management of paediatric HIV. The comprehensive approach on preventing mother-to-child transmission (PMTCT) has clearly reduced the number of children acquiring the infection in Italy. Although further reduction of MTCT should be attempted, efforts to personalize intervention to specific cases are now required in order to optimise the treatment and care of HIV-infected children. The prompt initiation of treatment and careful selection of first-line regimen, taking into consideration potency and tolerance, remain central. In addition, opportunistic infection prevention, adherence to treatment, and long-term psychosocial consequences are becoming increasingly relevant in the era of effective antiretroviral combination therapies (ART). The increasing proportion of infected children achieving adulthood highlights the need for multidisciplinary strategies to facilitate transition to adult care and maintain strategies specific to perinatally acquired HIV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514509     DOI: 10.1007/s15010-010-0020-5

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  106 in total

1.  Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.

Authors:  Andrea Kovacs; Grace Montepiedra; Vincent Carey; Savita Pahwa; Adriana Weinberg; Lisa Frenkel; Edmund Capparelli; Lynne Mofenson; Elizabeth Smith; Kenneth McIntosh; Sandra K Burchett
Journal:  J Infect Dis       Date:  2005-06-14       Impact factor: 5.226

2.  The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies.

Authors:  W Andiman; Y Bryson; M de Martino; M Fowler; D Harris; C Hutto; B Korber; A Kovacs; S Landesman; M Lindsay; N Lapointe; L Mandelbrot; M-L Newell; H Peavy; J Read; C Rudin; A Semprini; R Simonds; R Tuomala
Journal:  N Engl J Med       Date:  1999-04-01       Impact factor: 91.245

3.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Authors:  Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher
Journal:  J Infect Dis       Date:  2005-08-15       Impact factor: 5.226

4.  Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999.

Authors:  Richard M Selik; Mary Lou Lindegren
Journal:  Pediatr Infect Dis J       Date:  2003-07       Impact factor: 2.129

5.  Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial.

Authors:  Anita De Rossi; A Sarah Walker; Nigel Klein; Davide De Forni; Doug King; Diana M Gibb
Journal:  J Infect Dis       Date:  2002-07-05       Impact factor: 5.226

6.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

7.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

8.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

9.  Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

Authors:  Russell B Van Dyke; Lu Wang; Paige L Williams
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

10.  Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis.

Authors: 
Journal:  Arch Pediatr Adolesc Med       Date:  2002-09
View more
  2 in total

1.  Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort.

Authors:  S Leone; G Gregis; G Quinzan; D Velenti; G Cologni; L Soavi; V Ravasio; D Ripamonti; F Suter; F Maggiolo
Journal:  Infection       Date:  2011-01-19       Impact factor: 3.553

2.  Post-licensing safety of fosamprenavir in HIV-infected children in Europe.

Authors:  Ali Judd; Trinh Duong; Luisa Galli; Tessa Goetghebuer; Luminita Ene; Antoni Noguera Julian; Jose Tomas Ramos Amador; Jeanne Marie Pimenta; Claire Thorne; Carlo Giaquinto
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03       Impact factor: 2.890

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.